Rendu Bio released its 2026 interim report. Net profit attributable to the parent for the first half was 9.58 million yuan, up 369.9% year-on-year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 4.28 million yuan in the same period last year to a profit of 1.37 million yuan. First-half operating revenue was 79.44 million yuan, down 2.2% year-on-year. Net operating cash flow was negative 2.05 million yuan, down 97.2% year-on-year. Earnings per share were 0.239 yuan. In the second quarter, operating revenue was 37.36 million yuan, down 7.9% year-on-year. Net profit attributable to the parent was 4.58 million yuan, up 460.6% year-on-year, and the loss in net profit attributable to the parent after deducting non-recurring items narrowed. As of the end of the second quarter, total assets were 948 million yuan, down 4.2% from the end of the previous year. Net assets attributable to the parent were 884 million yuan, down 3.3% from the end of the previous year. The company continued to focus on RNA isothermal amplification technology, launched multiple new products in the molecular diagnostics reagent field, and drove profit growth through cost reduction and efficiency improvement measures.
Shanghai Rendu Biotechnology Co. Ltd. ANet profit attributable to parent surged 369.9% YoY, swinging to profit after deducting non-recurring items.